Mixed response to osimertinib and the beneficial effects of additional local therapy

Background Although non‐small cell lung cancers (NSCLCs) harboring EGFR mutations initially respond well to EGFR‐tyrosine kinase inhibitors (TKIs), they typically progress after approximately one year. The EGFR T790M mutation is the most common resistance mechanism. NSCLCs with T790M respond well to...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Yuki Shinno, Yasushi Goto, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2019-04-01
Serier:	Thoracic Cancer
Fag:	Epidermal growth factor receptor mixed response non‐small cell lung cancer oligoprogressive disease osimertinib
Online adgang:	https://doi.org/10.1111/1759-7714.12991
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!